奇正消痛贴膏治疗膝骨性关节炎的临床疗效和安全性观察  被引量:9

The clinical efficacy and safety observation of Qizheng Xiaotong Plaster in the treatment of knee osteoarthritis

在线阅读下载全文

作  者:张晓[1] 李慧[1] 张嘉良[1] 

机构地区:[1]广东省第二中医院白云院区骨科,广东广州510405

出  处:《中国当代医药》2011年第24期115-116,共2页China Modern Medicine

摘  要:目的:观察奇正消痛贴膏治疗膝骨关节炎的疗效和安全性。方法:采用开放试验,观察30例膝骨关节炎患者应用奇正消痛贴膏治疗7d(1贴/d)的疗效和安全性。观察指标为骨关节炎膝关节休息痛和活动痛VAS评分,药物起效时间、疼痛明显缓解时间、患者对疗效的总体评价、压痛及肿胀指数,并记录研究期间内所有不良事件。结果:治疗前患膝休息痛和活动痛VAS评分分别为(4.20±2.12)分及(6.46±2.53)分,治疗7d后分别为(1.38±1.44)分及(3.21±1.65)分(P<0.05)。患者对疗效的综合评价为有效率为100%,显效率为80%。首次给药后疼痛缓解平均时间为(1.94±1.1)d。全部受试者均未出现全身不良反应。结论:奇正消痛贴膏治疗膝骨关节炎止痛效果良好,安全性好。Objective: To observe the clinical efficacy and safety of Qizheng Xiaotong Plaster in the treatment of knee osteoarthritis. Methods: The open experiment was used for the observation of clinical efficacy and safety of 30 cases knee osteoarthritis which was treated with Qizheng Xiaotong Plaster after seven days and one plaster per day. The observation index included VAS scale of knee osteoarthritis rest pain and knee osteoarthritis pain, the onset time of drug, the time of pain significant relief, the patient’s overall assessment of efficacy, tenderness and swelling index, meanwhile, all adverse events was recorded during the study period. Results: Before treatment, the VAS scale of knee osteoarthritis rest pain and osteoarthritis pain was (4.20±2.12) point and (6.46±2.53) point , respectively. After 7 days treatment, the data was (1.38 ± 1.44) points and (3.21 ± 1.65) point (P〈0.05). The overall assessment of patient on the efficacy was 100% and effective rate was 80%. The time of pain relief after first administration was (1.94±1.1) days in average. No subject had systemic adverse reactions. Conclusion: Qizheng Xiaotong Plaster has good effect and safety on the treatment of knee osteoarthritis.

关 键 词:骨关节炎 奇正消痛贴膏 疗效 安全性 

分 类 号:R684.3[医药卫生—骨科学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象